Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
Phase 2
Terminated
NCT04414514
| Condition | Hidradenitis Suppurativa |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | Milton S. Hershey Medical Center |
|---|
| Status | Terminated |
|---|
| Enrollment | 6 participants |
|---|
| Interventions | Ruxolitinib 1.5% Cream |
|---|
| Start date | Oct 13, 2022 |
|---|
| Completion date | Feb 23, 2024 |
|---|
| Results posted | Apr 28, 2026 |
|---|
Summary
Investigators hypothesize that ruxolitinib 1.5% cream is an effective therapy for HS participants through inhibition of inflammatory activity. Investigators aim to: * Demonstrate the clinical efficacy of ruxolitinib 1.5% cream in decreasing the clinical disease activity after 16 weeks of treatment. * Investigate the impact of ruxolitinib 1.5% cream on skin inflammation through translational analyses of skin biopsy samples.
Number of Participants With Hidradenitis Suppurativa Clinical Response (HiSCR)
16 weeks after treatment. · Participants
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.